Your browser doesn't support javascript.
loading
Obesity Paradox in Transcatheter Aortic Valve Replacement.
Madanat, Luai; Jabri, Ahmad; Hanson, Ivan D; Khalili, Houman; Rodés-Cabau, Josep; Pilgrim, Thomas; Okuno, Taishi; Elmariah, Sammy; Pibarot, Philippe; Villablanca, Pedro; Abbas, Amr E.
Affiliation
  • Madanat L; William Beaumont University Hospital, Corewell Health East, Royal Oak, MI, USA.
  • Jabri A; Department of Cardiovascular Medicine, Henry Ford Hospital, Detroit, MI, USA.
  • Hanson ID; William Beaumont University Hospital, Corewell Health East, Royal Oak, MI, USA.
  • Khalili H; Florida Atlantic University and Memorial Cardiovascular Institute, Hollywood, FL, USA.
  • Rodés-Cabau J; Université Laval/Québec Heart and Lung Institute, Laval, Québec, Canada.
  • Pilgrim T; Bern University Hospital, Bern, Switzerland.
  • Okuno T; Bern University Hospital, Bern, Switzerland.
  • Elmariah S; University of San Francisco, San Francisco, CA, USA.
  • Pibarot P; Université Laval/Québec Heart and Lung Institute, Laval, Québec, Canada.
  • Villablanca P; Department of Cardiovascular Medicine, Henry Ford Hospital, Detroit, MI, USA.
  • Abbas AE; William Beaumont University Hospital, Corewell Health East, Royal Oak, MI, USA. Amr.Abbas@corewellhealth.org.
Curr Cardiol Rep ; 2024 Jul 29.
Article in En | MEDLINE | ID: mdl-39073506
ABSTRACT

BACKGROUND:

Obesity paradox in cardiovascular risk prediction has gained increasing attention in recent years. We aimed to investigate the impact of BMI on mortality following transcatheter aortic valve replacement (TAVR).

METHODS:

We performed a multi-center retrospective analysis of patients with severe aortic stenosis undergoing TAVR. Patients were categorized into Underweight (BMI < 18.5), normal weight (18.5 ≤ BMI < 25), overweight (25 ≤ BMI < 30) and obese (BMI ≥ 30). Multivariate cox-proportional hazard model was used to compare all-cause mortality.

RESULTS:

Total of 6688 patients included (175 underweight, 2252 normal weight, 2368 overweight and 1893 with obesity). Mean age of patients was 81 ± 8 years with 55% males. Patients with obesity had higher prevalence of comorbidities but a lower overall STS score. Mortality at 30-days post-TAVR was lower in the obese population compared to underweight, normal weight, and overweight patients (1.6% vs. 6.9%, 3.6%, and 2.8%, respectively, p < 0.001). Similarly, 3-year mortality was lowest in patients with obesity (17.1% vs. 28.9%, 24.5% and 18.6%, respectively, p < 0.001). On multivariate analysis, long term all-cause mortality at 3-years remained significantly lower in patients with obesity compared to underweight (HR 1.74, 95% CI 1.30-2.40, p < 0.001) and normal weight (HR 1.41, 95% CI1.21-1.63, p < 0.001) but not in overweight patients (HR 1.10, 95% CI0.94-1.28, p = 0.240).

CONCLUSION:

In conclusion, patients with obesity have improved short and long term mortality following TAVR with an observed progressive increase in mortality with lower BMI ranges.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Curr Cardiol Rep Journal subject: CARDIOLOGIA Year: 2024 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Curr Cardiol Rep Journal subject: CARDIOLOGIA Year: 2024 Type: Article Affiliation country: United States